Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 823.48M | 720.76M | 534.58M | 393.95M | 391.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 823.48M | 720.76M | 534.58M | 393.95M | 391.82M |
| Cost of Revenue | 107.73M | 95.21M | 81.39M | 58.04M | 47.82M |
| Gross Profit | 715.76M | 625.55M | 453.19M | 335.92M | 344.00M |
| SG&A Expenses | 523.16M | 446.50M | 390.69M | 348.60M | 314.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 977.61M | 877.26M | 810.29M | 753.00M | 694.54M |
| Operating Income | -154.13M | -156.50M | -275.71M | -359.04M | -302.73M |
| Income Before Tax | -236.35M | -245.12M | -285.98M | -363.73M | -404.79M |
| Income Tax Expenses | 17.69M | 10.87M | 7.76M | 3.64M | 5.25M |
| Earnings from Continuing Operations | -254.05 | -255.99 | -293.74 | -367.37 | -410.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -254.05M | -255.99M | -293.74M | -367.37M | -410.04M |
| EBIT | -154.13M | -156.50M | -275.71M | -359.04M | -302.73M |
| EBITDA | -138.34M | -140.81M | -259.92M | -343.42M | -287.02M |
| EPS Basic | -4.20 | -4.25 | -4.97 | -6.29 | -7.14 |
| Normalized Basic EPS | -2.53 | -2.54 | -3.03 | -3.89 | -4.40 |
| EPS Diluted | -4.20 | -4.25 | -4.97 | -6.29 | -7.14 |
| Normalized Diluted EPS | -2.51 | -2.52 | -3.00 | -3.82 | -4.33 |
| Average Basic Shares Outstanding | 242.25M | 241.01M | 237.79M | 234.68M | 231.55M |
| Average Diluted Shares Outstanding | 245.71M | 244.47M | 241.25M | 238.14M | 235.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |